May 2, 2023 11:31 AM EDTUpdated 01:12 PM
People

Ex­elix­is gives more de­tails be­hind Far­al­lon proxy fight

Paul Schloesser

Associate Editor

On­col­o­gy biotech Ex­elix­is is de­fend­ing its busi­ness amid a proxy fight with a hedge fund that has crit­i­cized the com­pa­ny’s R&D strat­e­gy and spend­ing. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times